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Additional Sources 
Clinical Presentation 
It is possible many cases of Type B 
lactic acidosis are missed or caught later 
than necessary.  It is possible that with 
early differential diagnosis and 
recognition, RCTs might be instituted to 
identify more efficacious treatment 
modalities improving mortality rates 
with this disease process. Although this 
is a basic review of Type B lactic acidosis 
for the purpose of increased awareness, 
theory and research point to more 
specific biochemical mechanisms, and 
readers are encouraged to explore this 
topic to a desired level of interest and 
comfort.   
 
The most common and best known form of 
lactic acidosis, Type A, presents in the 
environment of tissue hypoxia.  The lesser 
known form, Type B, does not involve tissue 
hypoxia, is not well understood, and very often 
results in death.  No randomized controlled 
trials (RCTs) comparing treatment modalities 
currently exist (Ruiz, Singh, & Hart, 2011).  
Increased recognition by medical and nursing 
disciplines may result in quicker diagnosis, 
opportunity to implement treatment, possibility 
for RCTs, and better outcomes. 
 
•  History of leukemia or lymphoma, less often 
solid tumors.  See Table 1 
 
•  Signs of relapse or worsening oncologic 
conditions: pancytopenia, lymphandopathy 
 
•  Associated diffuse symptoms including (not 
exhaustive): fatigue, bleeding, myalagias, edema 
 
•  Non-oncologic etiologies: medications, other 
disease processes, hereditary or metabolic 
disorders, and thiamine deficiencies related to 
alcohol use or chemotherapy administration. See 
Table 2 
 
•  Presentation with lactic acidosis, an anion gap, 
and normal blood pressure 
 
• Acute respiratory distress and no identifiable 
pulmonary source (Friedenberg, Douglas, 
Brandoff, & Schiffman, 2007). 
 
 Otterbein University, Westerville, Ohio  
Number of 
cases 
Percent of 
Total Cases 
Hematologic Malignancies 27 87 
Lymphoma 18 58 
Non-Hodgkin’s Lymphoma 17 55 
Hodgkin’s Lymphoma 1 3 
Leukemias 8 26 
Acute Lymphoblastic 
Leukemia 
5 16 
Acute Myeloid Leukemia 2 6 
Chronic Lymphocytic  
Leukemia 
1 3 
Multiple Myeloma 1 3 
Solid Malignancies 4 13 
Table 1. Summary of Case Reports of Type B Lactic Acidosis 
from 2000 to 2010 
Conclusions 
 
• Awareness that treatment involves 
addressing the underlying cause, often 
with chemotherapy, occasionally with 
thiamine supplementation. 
 
• Supportive treatments include: renal 
replacement therapy, bicarbonate 
administration, and respiratory support 
(Tang, et al., 2013). 
 
• As presently patients with this 
diagnosis tend to have poor outcomes, 
often death, (Kumar & Raina, 2014), in 
addition to high-acuity care, nursing 
interventions might lean toward 
supportive end-of-life psychosocial 
interventions. 
 
Implications for  
Nursing Care 
    In normal anaerobic conditions, 
glucose degradation produces lactic acid, 
in normal aerobic conditions, it does not, 
see Figure 1.   Lactic acid is continually 
produced and broken down.  Lactic 
acidosis occurs when this balance is 
disturbed; causes include 
overproduction, underutilization, or both.  
Lactic acidosis is defined as whole blood 
level lactic acid > 5 mmol/L and a pH <  
7.30 (Sia, Plumb, & Filaus, 2013). 
    Discovered by Otto Van Warburg, in 
1924, and named the Warburg Effect, 
cancer cells will sometimes take an 
anaerobic pathway even in the presence 
of oxygen, see Figure 2, a.  It is not known 
why this effect occurs, but it is theorized 
that the process might improve tumor 
proliferation (Ruiz et al., 2011).  
Alternatively, quickly growing tumors 
might overgrow their blood and thus 
oxygen supply (Kumar & Raina, 2014).  
Regardless, the Warburg effect results in 
the overproduction lactate.  
    Other potential causes of the over-
production of lactic acid include 
increased viscosity of blood in the case of 
leukemias potentiating microvascular 
aggregates, in fact producing a Type A 
hypoxic lactic acidosis (Ustin et al., 2002).  
Underlying Pathophysiology 
     Vitamin deficiency, in particular thiamin, 
is associated with the increased production 
of lactate.  As can be seen below in Figure 2, 
c, the absence of thiamin pushes 
metabolism toward the anaerobic pathway.  
Another theory posits that tumor necrosis 
factor may alter enzymatic levels which 
push pyruvate toward the aerobic process 
(Hae et al., 2010).  In yet another theorized 
cause, tumor tissue may overproduce 
insulin-like growth factor, altering 
mitochondrial respiration (Kumar and 
Raina, 2014).  
    Related to problems of decreased lactic 
acid degradation or removal, normally the 
liver either converts lactate back to glucose 
or oxidizes lactate to carbon dioxide and 
water (Ustun et al., 2002).  The liver 
manages 80-90% of lactate clearance, the 
kidneys manage the remainder.  As the 
liver and kidney contribute to 
gluconeogenesis and lactate clearance, 
dysfunction in these organs can result in 
lactate underutilization, see Figure 2, b.  
Often this dysfunction involves tumor 
involvement (Kuo, Yeh, & Lin, 2014).  
However, there may be another, non-
structural process at work in the liver (Ruiz 
et al, 2011). 
Figure 2. Changes in Glucose Metabolism Contributing to Type B Lactic Acidosis 
• In-depth knowledge of this 
pathophysiology remains speculative 
 
• Type B lactic acidosis potentially has 
multiple contributing factors 
 
• Mortality rates are markedly high, 
81%, per Ruiz et al., 2011 
 
• Type B lactic acidosis is usually a 
diagnosis by exception, ruling out 
common causes of hypoxia in oncologic 
patients (sepsis, cardiomyopathy, 
hypovolemia) (Ustin et al, 2002).  
 
• Non-oncologic causes of Type B lactic 
acidosis, could produce a synergistic 
effect with oncologic causes 
 
• The current poor outcomes of this 
condition could be related to delays in 
diagnosis and treatment (Sia, et al., 
2013). 
 
Normal aerobic conditions: glucose  pyruvate + oxygen 
+ thiamin  ATP + carbon dioxide + water 
 
Normal anaerobic conditions: glucose  pyruvate  
ATP + lactic acid 
Adapted from Tang, Perry, and Akhtari  (2013)     
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Table 2. Non-oncologic Etiologies of Type B Lactic Acidosis 
Other medical 
diseases 
Liver failure 
Renal failure 
HIV 
Diabetes mellitus 
Medications or 
toxins 
Metformin 
Historically phenformin 
Nucleoside reverse transcriptase inhibitors 
Salicylates 
Linezolid 
Propofol 
Isoniazid 
Alcohol 
Cyanide 
Hereditary disorders 
Glucose 6-phosphate deficiency 
Frutose-1,6-diphosphate deficiency 
Pyruvate carboxylate deficiency 
Oxidative phosphorylation deficiencies 
Adapted from Friendenberg, et al. (2007) 
Sia, et al. (2013) 
Figure 1. Metabolism of Glucose in Normal Conditions 
